Targets › CD37
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Nov 2027.
Structural component of specialized membrane microdomains known as tetraspanin-enriched microdomains (TERMs), which act as platforms for receptor clustering and signaling. Participates thereby in diverse biological functions such as cell signal transduction, adhesion, migration and protein trafficking. (UniProt, P11049)
Open in Phaseline: the race on CD37, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | Ottuzumab Anti-CD37 monoclonal antibody | CD37 | Phase 2 | Diffuse Large B-cell Lymphoma(DLBCL) | Nov 2027 |
Diffuse Large B-cell Lymphoma(DLBCL) (1)
small molecule (1)
The First Affiliated Hospital of Soochow University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.